Peer-Reviewed Publication
J Clin Pathol2026;79(5):291-298.April 17, 2026Journal Article
Quo Vadis colorectal intramucosal adenocarcinoma?
Vikram Deshpande1,2, Adrian C Bateman3, Munita Bal4, Runjan Chetty5, Maurice B Loughrey6,7, Jinru Shia8, Michael Vieth9, Monika Vyas10,2, Yoh Zen11
1Pathology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA vdeshpan@bidmc.harvard.edu.
2Harvard Medical School, Boston, Massachusetts, USA.
3Cellular Pathology, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
4Pathology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.
5Diagnexia Pty, Ltd, Oxford, UK.
6Department of Cellular Pathology, Royal Victoria Hospital, Belfast, UK.
7Centre for Public Health, Queen's University, Belfast, UK.
8Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
9Institute for Pathology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Klinikum Bayreuth GmbH, Bayreuth, Germany.
10Pathology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
11Liver Institute, King's College Hospital, London, UK.
Abstract
The classification and clinical implications of colorectal intramucosal adenocarcinoma remain controversial. Given the increasing frequency of diagnosis through colorectal cancer screening programmes, a reassessment of terminology and its impacts is necessary. This paper critically examines the diagnostic criteria, biological behaviour and clinical consequences of labelling these lesions as colore…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans